Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Chubb
Moodys
Citi
US Army
Accenture

Generated: May 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,053,092

« Back to Dashboard

Which drugs does patent 7,053,092 protect, and when does it expire?

Patent 7,053,092 protects ABILIFY and ABILIFY MYCITE KIT and is included in four NDAs.

Summary for Patent: 7,053,092
Title:5-HT1a receptor subtype agonist
Abstract: The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT.sub.1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1): ##STR00001## wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.
Inventor(s): Jordon; Shaun (Germantown, MD), Kikuchi; Tetsuro (Tokushima, JP), Tottori; Katsura (Kamiita-cho, JP), Hirose; Tsuyoshi (Tokushima, JP), Uwahodo; Yasufumi (Tokushima, JP)
Assignee: Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:10/055,915
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,053,092
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,053,092
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,053,092

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Otsuka ABILIFY aripiprazole SOLUTION;ORAL 021713-001 Dec 10, 2004 DISCN Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Otsuka ABILIFY aripiprazole TABLET, ORALLY DISINTEGRATING;ORAL 021729-002 Jun 7, 2006 DISCN Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Otsuka ABILIFY aripiprazole TABLET, ORALLY DISINTEGRATING;ORAL 021729-003 Jun 7, 2006 DISCN Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Boehringer Ingelheim
Harvard Business School
Moodys
Chubb
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.